ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ

This combination of N-803 with BCG is ImmunityBios first BLA to reach this stage of FDA acceptance for review.